Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).

Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).

Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).

Osteoarthritis, Knee

Vitamin D Supplementation

Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.

Placebo

Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.

Vitamin D (cholecalciferol)

Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.

Glucosamine sulfate and omega-3 fatty acids

Vitamin D Supplementation in Knee Osteoarthritis

The Influence of Vitamin D Supplementation With and Without Glucosamine Sulfate and Omega-3 Fatty Acids in Patients With Osteoarthritis Symptoms

The influence of supplemental vitamin D on serum IL-10 concentration (pg/mL) in subjects with knee osteoarthritis.

The influence of supplemental vitamin D on single-leg peak isokinetic torque (Nm at 60 degrees per second) in subjects with knee osteoarthritis.

Patient reported pain and physical dysfunction (using the subsection questions in the WOMAC survey) will be reported by each subject.

Supplemental vitamin D influences serum cytokines (pg/mL) in subjects with knee OA

Supplemental vitamin D influences single leg peak isometric force (N) in subjects with knee osteoarthritis.

Supplemental vitamin D influences serum soluble cytokine receptors (sIL-1r, sIL-1r2, sIL-4r, sIL-6r, sTNFr1, and sTNFr2: pg/mL)

Supplemental vitamin D influences single leg peak output (Nm) in subjects with knee osteoarthritis.

Intermountain Health Care, Inc.

USANA Health Sciences

This study consists of a double-blind, placebo-controlled experimental design. Subjects will be randomly assigned to one of three groups: (#1) vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids), (#2) vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements, or (#3) matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements will be taken daily for 84 days (12 weeks). Groups will be permuted in random blocks of six.

Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.

Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.

Chronic Kidney Disease stage3 and 4

Type 2 Diabetes Mellitus

Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years

pentoxifylline

Cibimi - Hgz 83 Imss

Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)

Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy

It will be measure as to duplicate serum creatinine levels from baseline (mg/dL), or to pass from a stage of chronic kidney disease to he next stage (GFR mL/min)

The change in vit C level from baseline (normal range 4-8.8mg/ L)

Change in Nt_ProBNP from the baseline (Normal values up to 381 pg/mL)

To assess inflammation high sensitivity C reactive protein will be measured by nephelometry. (normal value < 5 mg/L

This outcome will be measured by the SF 36 questionnaire, themaximun punctuation is 100, as greater punctuation a better quality of life

The individual participant data for all primary and secondary outcome measures will be made available

Maria Eugenia Galván Plata

Coordinacion de Investigacion en Salud, México

Centro de Investigación Biomédica de Michoacán.

Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.

Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.

Coordinación Auxiliar Medica de Investigación en Salud. Delegación Michoacán.

blinded,multicenter, randomized, pentoxifylline vs placebo controlled clinical trial. Time: two years after the enrollment of the last patient.

glucosamine/nekrosis

Vitamin D Supplementation in Knee Osteoarthritis

Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)

Database tanaman obat terlengkap yang didukung oleh sains